{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"51"},{"groupId":"OG002","value":"87"},{"groupId":"OG003","value":"83"},{"groupId":"OG004","value":"96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"53"},{"groupId":"OG003","value":"103"},{"groupId":"OG004","value":"106"}],"units":"Participants"}],"description":"Detection rate was defined as proportion of 68Ga-PSMA-11 PET positive patients, independent of the reference standard stratified by PSA value (0.2-\\<0.5; 0.5-\\<1.0; 1.0-\\<2.0; 2.0-\\<5.0, and ≥5.0).","groups":[{"description":"Patients whom have a PSA nadir value of \\<0.5","id":"OG000","title":"PSA <0.5"},{"description":"Patients whom have a PSA nadir value of 0.5 to \\<1.0","id":"OG001","title":"PSA 0.5 - <1.0"},{"description":"Patients whom have a PSA nadir value of 1.0 to \\<2.0","id":"OG002","title":"PSA 1.0 - <2.0"},{"description":"Patients whom have a PSA nadir value of 2.0 - \\<5.0","id":"OG003","title":"PSA 2.0 - <5.0"},{"description":"Patients whom have a PSA nadir value of ≥5.0","id":"OG004","title":"PSA ≥5.0"}],"paramType":"NUMBER","populationDescription":"Portion of patients with 68Ga-PSMA-11 PET positive findings were stratified by PSA range and disease location in accordance with Prostate Magnetic Resonance Imaging Study (PROMIS)","reportingStatus":"POSTED","timeFrame":"1 month","title":"Detection Rates of 68Ga-PSMA-11 PET Stratified by Prostate-specific Antigen (PSA) Value","type":"SECONDARY","unitOfMeasure":"percentage detected"}